Circassia Pharmaceuticals's market cap is currently ―. The company's EPS TTM is p0.025; its P/E ratio is 27.77; Circassia Pharmaceuticals is scheduled to report earnings on September 25, 2024, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Jun 22	Dec 21	Jun 21	Dec 20
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	-	-	-	-	-
EBITDA	-	-	-	-	-
Net Income Common Stockholders	-	-	-	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	£ 19.40M	£ 13.80M	£ 12.60M	£ 11.30M	£ 7.40M
Total Assets	£ 98.50M	£ 92.20M	£ 86.40M	£ 89.50M	£ 103.10M
Total Debt	£ 1.00M	£ 1.50M	£ 1.30M	£ 1.70M	£ 1.60M
Net Debt	£ -18.40M	£ -12.30M	£ -11.30M	£ -9.60M	£ -5.80M
Total Liabilities	£ 16.60M	£ 19.00M	£ 19.60M	£ 24.30M	£ 37.00M
Stockholders Equity	£ 81.90M	£ 73.20M	£ 66.80M	£ 65.20M	£ 66.10M
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in GBP

Circassia Pharmaceuticals Earnings and Revenue History

Income Statement >

Circassia Pharmaceuticals Debt to Assets

Balance Sheet >

Circassia Pharmaceuticals Cash Flow

Cash Flow >

Circassia Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing